WO2024184817 - MEDICAMENT AND MEDICAMENT COMBINATION FOR USE IN THE TREATMENT OF INFECTIOUS DISEASE
National phase entry is expected:
Publication Number
WO/2024/184817
Publication Date
12.09.2024
International Application No.
PCT/IB2024/052145
International Filing Date
06.03.2024
Title **
[English]
MEDICAMENT AND MEDICAMENT COMBINATION FOR USE IN THE TREATMENT OF INFECTIOUS DISEASE
[French]
MÉDICAMENT ET ASSOCIATION DE MÉDICAMENTS DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'UNE MALADIE INFECTIEUSE
Applicants **
THE SECRETARY OF STATE FOR DEFENCE
DSTL Porton Down
Salisbury Wiltshire SP4 0JQ, GB
Inventors
D'ELIA, Ricardo Vincenzo
DSTL IP Group
G02 Building 005
Salisbury Wiltshire SP4 0JQ, GB
Priority Data
2303291.5
07.03.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 934 | |
| EPO | Filing, Examination | 4639 | |
| Japan | Filing | 535 | |
| South Korea | Filing | 576 | |
| USA | Filing, Examination | 2635 |
Total: 9319 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention is concerned with new medicaments, and especially new medicament combinations, i.e. a medicament comprising at least two therapeutic components. The new medicament combination is especially effective against Melioidosis.[French]
La présente invention concerne de nouveaux médicaments et, en particulier, de nouvelles associations de médicaments, c'est-à-dire un médicament comprenant au moins deux composants thérapeutiques. La nouvelle association de médicaments est particulièrement efficace contre la mélioïdose.